IP Library Granted Patent US 9,663,492
Granted Patent B2
US 9,663,492 · App. 14/969,720 · Granted May 30, 2017

Methods for the preparation of charged crosslinkers

Inventors: Wei Li (Acton, MA); Robert Yongxin Zhao (Lexington, MA)
Assignee: ImmunoGen, Inc.
C07D401/12C07D207/452C07D207/46C07D213/71C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,663,492
App. No.
14/969,720
Granted
May 30, 2017
Kind
B2
Abstract

Processes for the preparation of charged crosslinkers bearing a sulfonic acid moiety are disclosed. These procedures also optionally include methods to convert the resulting products to substantially a single salt form.

Claims (23)

1. A process for the preparation of a compound represented by formula (V):

or a salt thereof, comprising the steps of:

a) reacting a compound of formula (2a):

or a salt thereof, with a sulfonating agent to form a compound of formula (IV):

or a salt thereof;

b) reacting the compound of formula (IV), or a salt thereof, with N-hydroxysuccinimide in the presence of a base to form a salt of the compound of formula (V); and

c purifying the salt of the compound of formula (V) by crystallization in the presence of an acid to form the neutral form of the compound of formula (V).

2. The process of claim 1 , wherein the sulfonating agent is chlorosulfonic acid or sulfur trioxide.

3. The process of claim 1 , wherein the sulfonating agent is chlorosulfonic acid.

4. The process of claim 3 , wherein the sulfonating reaction is carried out in the presence of PySSPy.

5. The process of claim 4 , wherein about 0.5 equivalent of PySSPy is present.

6. The process of claim 3 , wherein the reaction between the compound of formula (IV) and N-hydroxysuccinimide is carried out in the presence of a coupling agent.

7. The process of claim 6 , wherein the coupling agent is selected from N,N′ -dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N,N′ -disopropyl carbodiimide (DIC) and 1-ethoxycarbonyl-1-2-ethoxy-1,2-dihydroquinoline (EEDQ).

8. The process of claim 7 , wherein the coupling agent is EDC.

9. The process of claim 1 , wherein the base is diisopropylethylamine (DIPEA).

10. The process of claim 1 , wherein the process comprises the steps of:

a)reacting the compound of formula (2a) or a salt thereof with chlorosulfonic acid to form the compound of formula (IV); and

b) reacting the compound of formula (IV) with N-hydroxysuccinimide in the presence of EDC to form the compound of formula (V).

11. The process of claim 1 , wherein the acid is HCl.

12. The process of claim 11 , wherein the acid is HCl.

13. The process of claim 1 , wherein the crystallization is carried out in a mixture of an organic solvent and water.

14. The process of claim 11 , wherein the crystallization is carried out in a mixture of an organic solvent and water.

15. The process of claim 12 , wherein the crystallization is carried out in a mixture of an organic solvent and water.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Feb 12, 2024
From: BIOPHARMA CREDIT PLC
To: IMMUNOGEN, INC.; IMMUNOGEN SWITZERLAND GMBH
Reel/Frame 066553/0109 →
PATENT SECURITY AGREEMENT Recorded Apr 6, 2023
From: IMMUNOGEN, INC.; IMMUNOGEN SWITZERLAND GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 063282/0894 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2015
From: LI, WEI; ZHAO, ROBERT YONGXIN
To: IMMUNOGEN, INC.
Reel/Frame 037296/0528 →
Continuity (5)
Continuation 14539361 · Nov 12, 2014
Continuation 14045151 · Oct 3, 2013
Division 13315005 · Dec 8, 2011
Provisional Application 61421357 · Dec 9, 2010
Related Publication 20160272616A1 · Sep 22, 2016